70978-61-9Relevant articles and documents
Orally bioavailable Syk inhibitors with activity in a rat PK/PD model
Thoma, Gebhard,Veenstra, Siem,Strang, Ross,Blanz, Joachim,Vangrevelinghe, Eric,Berghausen, J?rg,Lee, Christian C.,Zerwes, Hans-Günter
, p. 4642 - 4647 (2015)
Design and optimization of benzo- and pyrido-thiazoles/isothiazoles are reported leading to the discovery of the potent, orally bioavailable Syk inhibitor 5, which was found to be active in a rat PK/PD model. Compound 5 showed acceptable overall kinase se
SUBSTITUTED BICYCLE HETEROCYCLIC DERIVATIVES USEFUL AS ROMK CHANNEL INHIBITORS
-
Page/Page column 118, (2018/06/06)
Disclosed are compounds of Formula (I) or a salt thereof, wherein R1 is (II) or (III); each W is independently NR1b or O; Z is a bond or CHR1d; and R1, R2, Rd, R3, L1, L2, R1a, R1b, R1c, and n are define herein. Also disclosed are methods of using such compounds as inhibitors of ROMK, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating cardiovascular diseases.
Design, Synthesis, and Biological Evaluation of Novel Selenium-Containing Isocombretastatins and Phenstatins as Antitumor Agents
Pang, Yanqing,An, Baijiao,Lou, Lanlan,Zhang, Junsheng,Yan, Jun,Huang, Ling,Li, Xingshu,Yin, Sheng
, p. 7300 - 7314 (2017/09/22)
Two series of structurally related organoselenium compounds designed by fusing the anticancer agent methyl(phenyl)selane into the tubulin polymerization inhibitors isocombretastatins or phenstatins were synthesized and evaluated for antiproliferative acti
